- Home
- HRMY vs SEMR Comparison
HRMY vs SEMR Comparison
Compare HRMY & SEMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- SEMR
- Stock Information
- Founded
- HRMY 2017
- SEMR 2008
- Country
- HRMY United States
- SEMR United States
- Employees
- HRMY N/A
- SEMR N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- SEMR EDP Services
- Sector
- HRMY Health Care
- SEMR Technology
- Exchange
- HRMY Nasdaq
- SEMR Nasdaq
- Market Cap
- HRMY 2.0B
- SEMR 1.4B
- IPO Year
- HRMY 2020
- SEMR 2021
- Fundamental
- Price
- HRMY $32.16
- SEMR $9.33
- Analyst Decision
- HRMY Strong Buy
- SEMR Buy
- Analyst Count
- HRMY 9
- SEMR 8
- Target Price
- HRMY $54.22
- SEMR $17.00
- AVG Volume (30 Days)
- HRMY 620.8K
- SEMR 828.8K
- Earning Date
- HRMY 08-05-2025
- SEMR 08-04-2025
- Dividend Yield
- HRMY N/A
- SEMR N/A
- EPS Growth
- HRMY 13.13
- SEMR N/A
- EPS
- HRMY 2.62
- SEMR 0.05
- Revenue
- HRMY $744,852,000.00
- SEMR $396,021,000.00
- Revenue This Year
- HRMY $20.10
- SEMR $21.84
- Revenue Next Year
- HRMY $18.01
- SEMR $18.46
- P/E Ratio
- HRMY $12.27
- SEMR $192.99
- Revenue Growth
- HRMY 20.62
- SEMR 22.75
- 52 Week Low
- HRMY $26.47
- SEMR $7.90
- 52 Week High
- HRMY $41.61
- SEMR $18.74
- Technical
- Relative Strength Index (RSI)
- HRMY 43.25
- SEMR 44.22
- Support Level
- HRMY $31.70
- SEMR $8.74
- Resistance Level
- HRMY $33.69
- SEMR $9.18
- Average True Range (ATR)
- HRMY 0.89
- SEMR 0.31
- MACD
- HRMY -0.10
- SEMR 0.02
- Stochastic Oscillator
- HRMY 37.30
- SEMR 64.29
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.